Medigen Competitors

Stocks . Taiwan . 
Stock . Medigen Vaccine Biologics
6547 Stock  TWD 37.75  0.10  0.27%   
Medigen Vaccine Biologics competes with Ruentex Development, Symtek Automation, WiseChip Semiconductor, Novatek Microelectronics, and Leader Electronics; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing Medigen Vaccine competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Medigen Vaccine to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Medigen Vaccine Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Medigen Vaccine competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
36.3037.7539.20
Details
Intrinsic
Valuation
LowRealHigh
31.7733.2241.53
Details
Naive
Forecast
LowNextHigh
36.4737.9239.38
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
35.8839.5643.23
Details

Medigen Vaccine Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Medigen Vaccine and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Medigen and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Medigen Vaccine Biologics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
9933
+ 0.85
3034
9933
+ 0.84
3058
9933
+ 0.82
5245
6209
+ 0.78
9945
3058
+ 0.77
5245
3034
+ 0.74
5245
  
High negative correlations   
9933
- 0.84
6438
6697
- 0.64
9933
3058
- 0.64
6438
3034
- 0.63
6438
6697
- 0.59
3034
5245
- 0.59
6438

Risk-Adjusted Indicators

There is a big difference between Medigen Stock performing well and Medigen Vaccine Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Medigen Vaccine's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
9945  0.98 (0.05) 0.00 (0.28) 0.00 
 0.00 
 1.80 
(2.13)
 7.35 
6438  2.70  0.79  0.23  5.89  2.07 
(3.53)
 9.79 
(3.99)
 17.42 
5245  1.52 (0.17) 0.00  1.34  0.00 
 0.00 
 2.89 
(3.45)
 14.50 
3034  1.06 (0.14) 0.00 (0.48) 0.00 
 0.00 
 1.97 
(2.55)
 8.21 
3058  1.34 (0.15) 0.00  1.69  0.00 
 0.00 
 2.79 
(2.89)
 8.09 
3152  1.84  0.21  0.02 (0.26) 1.78 
(2.33)
 4.35 
(2.94)
 12.61 
9933  0.66 (0.28) 0.00  2.61  0.00 
 0.00 
 1.53 
(1.67)
 3.64 
6118  1.88  0.19  0.06  0.59  1.77 
(2.46)
 4.25 
(3.35)
 14.22 
6697  1.32  0.14  0.03  0.60  1.62 
(1.63)
 3.46 
(2.85)
 15.29 
6209  0.99  0.00 (0.06) 0.10  1.24 
(1.05)
 1.98 
(2.15)
 5.38 
All Fundamental Data

Medigen Vaccine Competitive Analysis

The better you understand Medigen Vaccine competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Medigen Vaccine's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Medigen Vaccine's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
6547 9945 6438 5245 3034 3058 3152 9933 6118 6697
 0.27 
 37.75 
Medigen
 0.43 
 45.80 
Ruentex
 0.26 
 192.00 
Symtek
 2.01 
 34.05 
WiseChip
 0.21 
 488.50 
Novatek
 1.20 
 16.50 
Leader
 0.56 
 178.00 
Advanced
 0.25 
 40.40 
CTCI
 1.54 
 22.45 
Xander
 2.85 
 47.70 
Information
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Not too volatile
Very steady
Very steady
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Solid
Very Weak
Very Weak
Very Weak
Modest
Very Weak
OK
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Buy
Strong Hold
Strong Hold
Strong Buy
Strong Hold
Cautious Hold
Strong Hold
Strong Buy
Strong Buy
Current Ratio
9.72
1.67
1.49
1.29
2.06
1.25
5.71
1.12
N/A
N/A
Net Asset
5.3 B
191.78 B
6.18 B
1.71 B
120.59 B
5.24 B
4.52 B
87.42 B
2.68 B
N/A
Profit Margin
0.13
0.53
0.13
0.15
0.25
-0.0544
0.21
0.0274
0.0029
N/A
EBITDA
1.53 B
19.66 B
904.7 M
368.53 M
49.24 B
(114.34 M)
1.58 B
4.46 B
99.31 M
N/A
Operating Margin
0.0875
0.13
0.16
0.17
0.3
-0.042
0.24
0.0386
0.0028
N/A
Current Valuation
24.78 B
196.39 B
5.77 B
2.5 B
144.82 B
2.91 B
11.64 B
25.43 B
3.66 B
N/A
Price To Book
4.71
6.72
1.78
2.08
3.05
1.11
3.65
1.93
3.21
N/A
Retained Earnings
N/A
18.36 B
N/A
N/A
20.21 B
289 M
N/A
5.3 B
N/A
N/A
Current Asset
N/A
28.06 B
N/A
N/A
34.22 B
2.77 B
N/A
48.05 B
N/A
N/A
Five Year Return
N/A
N/A
4.68
4.56
6.09
N/A
3.82
5.36
N/A
N/A
Beta
0.89
0.77
1.16
0.94
1.12
0.92
1.47
0.22
0.96
N/A
Number Of Employees
16
26
N/A
275
30
29
395
50
15
N/A
Shares Outstanding
327.2 M
3.15 B
71.43 M
43.16 M
608.51 M
156.58 M
69.02 M
784.39 M
90.89 M
N/A
Cash Flow From Operations
579.89 M
6.07 B
678.36 M
325.69 M
41.72 B
(112.27 M)
995.38 M
14.56 B
346.54 M
N/A
Annual Yield
N/A
0.0303
0.0651
0.0857
0.14
0.0133
0.0376
0.0508
0.0078
N/A
Total Debt
286.54 M
31.94 B
76.21 M
31.69 M
293.66 M
156.45 M
N/A
15.02 B
N/A
N/A
Return On Equity
0.0662
0.24
0.22
0.19
0.42
-0.17
0.0952
0.18
0.0278
N/A
Z Score
48.6
2.4
54.0
42.6
N/A
6.0
N/A
1.2
3.0
N/A
Return On Asset
0.0209
0.0164
0.0797
0.0872
0.26
-0.0248
0.051
0.0255
0.0059
N/A
Book Value Per Share
17.52
6.68
49.64
27.7
100.74
9.27
50.83
22.02
11.34
N/A
Current Liabilities
N/A
16.96 B
N/A
N/A
10.2 B
2.13 B
N/A
38.02 B
N/A
N/A
Total Asset
5.3 B
191.78 B
6.18 B
1.71 B
120.59 B
5.24 B
4.52 B
87.42 B
2.68 B
N/A
Debt To Equity
0.062
2.24
0.31
0.17
1.0
57.3
N/A
76.0
N/A
N/A
Target Price
N/A
29.17
N/A
N/A
371.06
N/A
232.5
53.5
N/A
N/A
Last Dividend Paid
N/A
1.33
6.3
4.48
N/A
N/A
8.0
2.26
0.3
N/A
Shares Owned By Institutions
5.13
8.22
2.13
0.43
40.9
0.96
11.59
19.08
N/A
N/A
Market Capitalization
23.36 B
139.36 B
6.89 B
2.27 B
242.49 B
1.57 B
14.98 B
34.91 B
3.5 B
N/A
Price To Earning
34.63
8.82
13.75
17.43
13.01
0.68
20.77
20.93
N/A
N/A
Price To Earnings To Growth
N/A
-1.03
N/A
N/A
2.12
N/A
N/A
1.15
N/A
N/A
Price To Sales
10.51
4.83
1.14
1.64
1.54
0.34
7.93
0.36
0.33
N/A
Net Income
1.41 B
16.24 B
651.65 M
197.86 M
38.87 B
(321.88 M)
1.03 B
1.64 B
54.33 M
N/A
Earnings Per Share
0.91
5.08
10.29
5.1
57.16
-2.42
4.97
3.24
0.32
N/A
Shares Owned By Insiders
27.99
45.16
20.98
51.48
5.1
17.93
41.55
27.37
57.45
N/A
Revenue
3.28 B
27.29 B
4.91 B
1.45 B
135.37 B
4.72 B
2.85 B
70.54 B
9.44 B
N/A
Working Capital
N/A
11.1 B
N/A
N/A
24.02 B
644 M
N/A
10.03 B
N/A
N/A
Cash And Equivalents
2.12 B
7.39 B
1.41 B
139.05 M
20.45 B
810.93 M
2.41 B
18 B
N/A
N/A
Cash Per Share
9.95
2.35
23.02
3.08
33.6
4.94
34.98
23.62
N/A
N/A
Gross Profit
2.31 B
5.73 B
1.6 B
505.36 M
50.94 B
358.69 M
1.62 B
4 B
413.23 M
N/A
Day Typical Price
37.83
45.97
194.67
33.95
491.0
16.6
176.83
40.4
22.73
47.3
Accumulation Distribution
5164.05
26113.49
90692.12
336.79
25335.3
11106.54
4098.66
N/A
10275.84
4002.91
Daily Balance Of Power
0.1538
(0.40)
0.0556
(1.40)
0.1333
(0.50)
0.2222
(9,223,372,036,855)
(0.41)
(0.70)
Period Momentum Indicator
0.1
(0.20)
0.5
(0.70)
1.0
(0.20)
1.0
(0.10)
(0.35)
(1.40)
Rate Of Daily Change
1.0
1.0
1.0
0.98
1.0
0.99
1.01
1.0
0.98
0.97
Day Median Price
37.88
46.05
196.0
33.9
492.25
16.65
176.25
40.4
22.88
47.1
Price Action Indicator
(0.07)
(0.35)
(3.75)
(0.20)
(3.25)
(0.25)
2.25
(0.05)
(0.60)
(0.10)
Coefficient Of Variation
(428.43)
(4,732)
452.32
(1,419)
(1,446)
(1,113)
1556.8
(307.66)
1108.07
1169.77
Mean Deviation
1.13
0.9752
2.7
1.52
1.06
1.34
1.84
0.6612
1.88
1.32
Jensen Alpha
(0.38)
(0.05)
0.7877
(0.17)
(0.14)
(0.15)
0.2123
(0.28)
0.1935
0.1437
Total Risk Alpha
(0.58)
(0.24)
0.2205
(0.59)
(0.34)
(0.44)
(0.24)
(0.43)
(0.20)
(0.17)
Sortino Ratio
N/A
N/A
0.235
N/A
N/A
N/A
0.0172
N/A
0.0587
0.0299
Downside Variance
N/A
N/A
8.59
N/A
N/A
N/A
3.84
N/A
4.61
4.48
Standard Deviation
1.46
1.26
3.68
2.53
1.46
1.72
2.46
0.8679
2.77
2.2
Kurtosis
0.2749
0.7418
0.9682
6.89
3.2
(0.25)
2.95
0.3093
4.76
6.52
Potential Upside
1.91
1.8
9.79
2.89
1.97
2.79
4.35
1.53
4.25
3.46
Treynor Ratio
(1.54)
(0.28)
5.89
1.34
(0.48)
1.69
(0.26)
2.61
0.5869
0.5986
Maximum Drawdown
7.39
7.35
17.42
14.5
8.21
8.09
12.61
3.64
14.22
15.29
Variance
2.12
1.58
13.53
6.41
2.15
2.96
6.05
0.7532
7.7
4.82
Market Risk Adjusted Performance
(1.53)
(0.27)
5.9
1.35
(0.47)
1.7
(0.25)
2.62
0.5969
0.6086
Risk Adjusted Performance
(0.16)
(0.01)
0.1677
(0.04)
(0.04)
(0.06)
0.0535
(0.23)
0.0726
0.0685
Skewness
(0.09)
0.0026
0.9126
1.67
(1.07)
0.1794
1.26
0.5001
1.75
1.29
Semi Deviation
N/A
N/A
2.07
N/A
N/A
N/A
1.78
N/A
1.77
1.62
Information Ratio
(0.32)
(0.12)
0.1873
(0.12)
(0.15)
(0.16)
0.0137
(0.47)
0.0454
0.0288
Value At Risk
(2.96)
(2.13)
(3.99)
(3.45)
(2.55)
(2.89)
(2.94)
(1.67)
(3.35)
(2.85)
Expected Short fall
N/A
N/A
(3.53)
N/A
N/A
N/A
(2.33)
N/A
(2.46)
(1.63)
Downside Deviation
N/A
N/A
2.93
N/A
N/A
N/A
1.96
N/A
2.15
2.12
Semi Variance
N/A
N/A
4.27
N/A
N/A
N/A
3.15
N/A
3.14
2.64

Medigen Vaccine Competition Performance Charts

Five steps to successful analysis of Medigen Vaccine Competition

Medigen Vaccine's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Medigen Vaccine Biologics in relation to its competition. Medigen Vaccine's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Medigen Vaccine in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Medigen Vaccine's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Medigen Vaccine Biologics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Medigen Vaccine position

In addition to having Medigen Vaccine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Sovereign ETFs Thematic Idea Now

Sovereign ETFs
Sovereign ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Medigen Stock Analysis

When running Medigen Vaccine's price analysis, check to measure Medigen Vaccine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigen Vaccine is operating at the current time. Most of Medigen Vaccine's value examination focuses on studying past and present price action to predict the probability of Medigen Vaccine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigen Vaccine's price. Additionally, you may evaluate how the addition of Medigen Vaccine to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY